What is Design-Zyme?
Design-Zyme LLC is a specialized biotechnology firm dedicated to the creation of advanced vaccines that emphasize both safety and effectiveness. The company's proprietary platform is engineered to tackle pressing public health concerns, including Chlamydia, opioid use disorder, and Lyme Disease. Leveraging a novel carbohydrate-based adjuvant, Design-Zyme's vaccine candidates are designed for versatile administration routes. Their research methodology is firmly rooted in data-driven principles and adheres strictly to FDA regulatory standards, supported by a multidisciplinary team of scientific experts. The company is actively pursuing strategic partnerships and investment to accelerate its mission of transforming vaccine performance.
How much funding has Design-Zyme raised?
Design-Zyme has raised a total of $37K across 1 funding round:
Debt
$37K
Debt (2021): $37K with participation from PPP
What's next for Design-Zyme?
With substantial expansion capital secured, Design-Zyme is poised for significant growth and development. The company's focus on a Series B/C stage indicates a transition towards scaling operations, potentially involving expanded clinical trials, manufacturing capabilities, and broader market penetration. Future strategic initiatives will likely center on advancing their vaccine pipeline through rigorous testing and regulatory approval processes. The company's commitment to addressing critical health challenges suggests a trajectory aimed at establishing new benchmarks in vaccine efficacy and safety, potentially attracting further investment and strategic alliances in the competitive biotech landscape.
See full Design-Zyme company page
